Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies

Quiambao, Beatriz P.; Nohynek, Hanna; Käyhty, Helena; Ollgren, Jukka; Gozum, Lorena S.; Gepanayao, Connie P; Soriano, Victoria C.; Mäkelä, P. Helena

doi:10.1016/j.vaccine.2007.03.021

Cited by 60 publications

(21 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the relative inefficiency of antibody transfer across the placenta, those studies which have examined the polysaccharide-specific IgG levels in the infant at delivery or prior to infant vaccination have generally reported higher antibody levels in the infants of mothers vaccinated during pregnancy compared to controls [43][44][45][46][47]. The half life of polysaccharide-specific antibody in the infant is subsequently variable and appears study-(or context) as well as pneumococcal serotype dependent.…”

Section: Maternal Vaccinationmentioning

confidence: 99%

Maternal and neonatal pneumococcal vaccination - where are we now?

Clarke

Kampmann

2016

Expert Review of Vaccines

View full text Add to dashboard Cite

Pneumococcus is a significant pathogen in neonates and in early infancy, particularly as a cause of invasive disease in sub-Saharan Africa where nasopharyngeal carriage rates are also exceptionally high. The pneumococcal-conjugate vaccines have now been rolled out in many high income settings and an increasing number of low and middle income countries. They have been highly effective at preventing vaccine serotype disease in infants. However, a window of susceptibility remains prior to the first vaccination at around six weeks of age. This paper summarizes the data available on both maternal and neonatal vaccination to prevent disease in newborns and early infancy and considers the key challenges and next steps for research in the field

show abstract

Section: Maternal Vaccinationmentioning

confidence: 99%

Maternal and neonatal pneumococcal vaccination - where are we now?

Clarke

Kampmann

2016

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…Immunization of pregnant women is a strategy that has been proven to reduce infection risks in both mothers and infants (9,13,45). This includes the potential to reduce acute lower respiratory illnesses in infants in high-risk areas, as shown with maternal immunization with the 23-valent pneumococcal polysaccharide vaccine (36,37). However, the efficacy of pneumococcal polysaccharide vaccines on reducing nasopharyngeal colonization is limited, whereas the protective effect of pneumococcal conjugate vaccines is restricted by the number of pneumococcal serotypes that can be included.…”

mentioning

confidence: 99%

Maternal Antibodies to Pneumolysin but Not to Pneumococcal Surface Protein A Delay Early Pneumococcal Carriage in High-Risk Papua New Guinean Infants

Francis

Richmond

Pomat

et al. 2009

Clin Vaccine Immunol

View full text Add to dashboard Cite

Immunization of pregnant women can be an efficient strategy to induce early protection in infants in developing countries. Pneumococcal protein-based vaccines may have the capacity to induce pneumococcal serotype-independent protection. To understand the potential of maternal pneumococcal protein-specific antibodies in infants in high-risk areas, we studied the placental transfer of naturally acquired antibodies to pneumolysin (Ply) and pneumococcal surface protein A family 1 and 2 (PspA1 and PspA2) in relation to onset of pneumococcal nasopharyngeal carriage in infants in Papua New Guinea (PNG). In this study, 76% of the infants carried Streptococcus pneumoniae in the upper respiratory tract within the first month of life, at a median age of 19 days. Maternal and cord blood antibody titers to Ply ( ‫؍‬ 0.824, P < 0.001), PspA1 ( ‫؍‬ 0.746, P < 0.001), and PspA2 ( ‫؍‬ 0.631, P < 0.001) were strongly correlated. Maternal pneumococcal carriage (hazard ratio [HR], 2.60; 95% confidence interval [CI], 1.25 to 5.39) and younger maternal age (HR, 0.74; 95% CI, 0.54 to 1.00) were independent risk factors for early carriage, while higher cord Ply-specific antibody titers predicted a significantly delayed onset (HR, 0.71; 95% CI, 0.52 to 1.00) and cord PspA1-specific antibodies a significantly younger onset of carriage in PNG infants (HR, 1.57; 95% CI, 1.03 to 2.40). Maternal vaccination with a pneumococcal protein-based vaccine should be considered as a strategy to protect high-risk infants against pneumococcal disease by reducing carriage risks in both mothers and infants.

show abstract

“…These data are derived from studies with tetanus toxoid, 28,29,[89][90][91][92][93] diphtheria toxoid, 94-100 whole cell pertussis, 101 diphtheria/tetanus/acellular pertussis (DTaP) 38,102 and pneumococcal polysaccharide vaccine. 57,81,[103][104][105][106][107][108][109][110] Inflammatory response follows the formation of immune complexes between the circulating antibodies and the injected antigen. This type of reaction is considered to be a Type III hypersensitivity reaction (Arthus reaction).…”

mentioning

confidence: 99%

Sex differences in injection site reactions with human vaccines

Cook¹

2009

Human Vaccines

View full text Add to dashboard Cite

Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies

Cited by 60 publications

References 37 publications

Maternal and neonatal pneumococcal vaccination - where are we now?

Maternal and neonatal pneumococcal vaccination - where are we now?

Maternal Antibodies to Pneumolysin but Not to Pneumococcal Surface Protein A Delay Early Pneumococcal Carriage in High-Risk Papua New Guinean Infants

Sex differences in injection site reactions with human vaccines

Contact Info

Product

Resources

About